Healthcare industry

Article - 13/05/2019

Innovation management in the life sciences – Inova DE provides insights

Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…

Article - 16/05/2018

Telemedical neurology council helps speed up stroke treatment

Stroke units save lives because specialist treatment is absolutely crucial for stroke patients. However, not all clinics have neurological specialists available 24/7, so telemedicine provides a good solution to the problem. Studies show that telemedical consultations can considerably improve the treatment of stroke patients.

Article - 19/04/2018

New combination therapy for treating stroke patients

30 to 40 percent of all stroke patients suffer from persistent signs of paralysis that prevents them from using the affected hand. The innovative combination of two non-invasive treatment methods is a therapeutic approach with considerable potential for treating severely impaired patients.

Article - 21/02/2018

HepaRegeniX – a start-up is taking it up a step!

HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.

Article - 29/01/2018

New test for extended blood fat analysis

Cholesterol is seen as the cause of atherosclerosis, a disease that can lead to heart attacks and strokes. However, it now seems that the way cholesterol is packaged may be even more important than high blood cholesterol levels. Nuclear magnetic resonance (NMR) spectroscopy now allows the high-throughput analysis of such lipid packages.

Article - 27/06/2016

A nasal spray for treating neurodegenerative diseases

Neuroscientists from Heidelberg have created the scientific foundations for a nasal spray that can stabilise the dendrites of nerve cells, thus reducing nerve damage and brain function losses following a stroke. Prof. Dr. Hilmar Bading and his team received the 2016 German BioRegions Innovation Prize for their invention and have set up a company called FundaMental Pharma to further accelerate the development of a marketable medicinal product.

CorTec just closed a new investment that will support bringing new personalized therapies for neurological diseases to patients. With Mangold Invest a new investor could be attracted who wants to go along that way with the young medical engineering company located in Freiburg. Equally convinced of the success of this project are the previous investors who are participating in this round of financing.

Article - 13/10/2014

Data mining is likely to play an increasing role in clinical development

Data mining still plays a minor role in the research-based pharmaceutical industry. But this is likely to change in the future. Mathematician Hans-Jürgen Lomp predicts that exploratory data analysis will be used to a greater extent in the future. Lomp is the Global Head of Statistics in Boehringer Ingelheim Pharma GmbH & Co KG’s Department of Medical Data Service and Biostatistics in Biberach.

Article - 30/06/2014

The German National Cohort: collecting data for a healthier future

A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early…

Article - 07/01/2014

Martin Scheffner: a biochemist exploring a versatile protein

Ubiquitin is found in almost all tissues and is involved in a wide variety of cellular processes e.g. protein degradation signal transduction and cell cycle control. The addition of ubiquitin alters the characteristics of proteins including their half life function or location. Prof. Dr. Martin Scheffners work is dedicated to the exploration of this versatile protein. The researcher from Konstanz studies the enzymes of the ubiquitin system and…

Article - 11/11/2013

Vitaphone GmbH - innovative telemedicine

Vitaphone GmbH from Mannheim is a leading international telemedical service provider. Its services range from telecardiological functional diagnostics, 24/7 telemonitoring of risk patients to integrative care management of chronically ill patients. Vitaphone is particularly involved in the application of structured telemonitoring-based therapy programmes for patients with heart failure.

Dossier - 19/08/2013

Telemedicine: advances in high-tech healthcare

Increasing average longevity, the growing number of chronic diseases and health economy issues are all generating an ever-increasing demand for inexpensive therapy options that are not time- or location dependent. For the past 10 years or so, telemedicine has been offering advanced solutions for a broad range of medical and health issues. Despite this progress, the use of telecommunication and information technologies in the provision of remote…

Article - 03/06/2013

Laser light for the diagnosis of stroke

Stroke is one of the most common causes of death in the Western world and in Germany the most common cause of moderate to severe disabilities. Besides effective prevention, the rapid and specific diagnosis of impaired blood circulation in the brain is key in the effective treatment of stroke patients. PD Dr. Thomas Gisler from the University of Konstanz has developed CereFLux, a method that allows the flow of blood in the human brain to be…

Article - 25/02/2013

Frauke Melchior and the SUMO wrestling match between proteins

Fifteen years ago, molecular biologist Frauke Melchior discovered a new mechanism of posttranslational protein modification that controls a variety of processes in eukaryotic cells. A small protein called SUMO is covalently bound to target proteins by specific enzymes and cleaved by other enzymes. This discovery has shaped Melchior’s scientific career.

Article - 04/02/2013

SYGNIS Pharma - the "new" one: development and commercialisation of molecular diagnostics products

Heidelberg-based SYGNIS Pharma AG is to discontinue its therapeutic R&D projects targeting human nervous system diseases and will in future focus on the research and development of novel molecular biology technologies, including DNA amplification and sequencing as well as drug screening.

Article - 28/12/2012

When cells go out of control – researchers to unveil the secret of cell ageing

The process of ageing appears, at least at first sight, to be fairly tangible and is visible both at individual and societal level. Nevertheless, science has not yet come up with detailed insights into the physiology of ageing. Jörg Bergemann, Professor of Biomedical Engineering at the Albstadt-Sigmaringen University of Applied Sciences, is studying the processes of ageing in skin cells in a project that has recently been granted funding by the…

Article - 22/10/2012

syneed imaging: precise visualisation of functional tissue properties

Functional medical imaging modalities are of great significance in modern medical diagnostics. Existing ways of diagnosing diseases are now being expanded with the arrival of the innovative parameter imaging method. syneed imaging uses proprietary highly sensitive software for the analysis of dynamic image data. This software complements standard methods such as computed tomography and magnetic resonance imaging and increases the significance of…

Dossier - 24/05/2012

Biochips: microsystems technology for the life sciences

Nanoscale robots and intelligent measurement systems in arteries, fingernail-sized DNA chips that can be used to analyze thousands of genes in tiny samples, intelligent DNA microsensors – the trend in the life sciences is moving towards miniaturization in all areas including electronics, sensor systems and the handling of liquids. Over the last few years, a research area with growing potential has developed at the interface of physics, the…

Article - 13/02/2012

A strange combination: green tea extract and light for treating Alzheimer’s

Andrei Sommer from the University of Ulm and colleagues from Ulm, Heidelberg and Berlin have succeeded in reducing amyloid beta deposits in human neuroblastoma cells by up to 60 per cent in vitro. The researchers found that the apparently strange combination of green tea and red light has the potential to lead to the development of new therapies for Alzheimer’s. There are currently no treatments available that stop or reverse the progression of…

Article - 19/12/2011

Lenhard Rudolph prepares four biomarkers for clinical application

Lenhard Rudolph’s biomarker quartet is extremely promising in terms of progressing medical and clinical treatment in ageing societies. The quartet - EF-1 alpha, Chi3L3, CRAMP and OP 18 – is made up of four proteins that can potentially be used as biomarkers. Specific concentrations of these molecules in human blood provide information on the biological age and renewal capacity of the tissue and organs of patients. The biomarker quartet also…

Press release - 14/12/2011

Towards a Therapy to Healing Stroke

The thalamus is the central translator in the brain: Specialized nerve cells (neurons) receive information from the sensory organs, process it, and transmit it deep into the brain. Researchers from the Institute of Toxicology and Genetics (ITG) of KIT have now identified the genetic factors Lhx2 and Lhx9 responsible for the development of these neurons. Their results contribute to understanding the development of the thalamus. In the long term,…

Press release - 15/07/2011

HITS Participates in a new DFG Research Unit on Blood Coagulation

Scientists from the Heidelberg Institute for Theoretical Studies participate in a new Research Unit on blood coagulation sponsored by the German Research Foundation (DFG). The aim of the DFG funding is to support a successful existing cooperation between scientists over several years.

SYGNIS Pharma AG a clinical stage biotech company developing innovative therapies for the treatment of neurodegenerative diseases today announced that it has licensed the exclusive rights to a European patent which will significantly expand SYGNIS IP-position with regard to its lead candidate AX200. AX200 which is known as the G-CSF protein is currently in a clinical phase II efficacy trial for the treatment of acute ischemic stroke.

Press release - 04/11/2010

Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today a comprehensive, strategic restructuring of the company, which will include significant personnel and cost reductions. The process has been approved by the Supervisory Board and will be executed immediately.